CoChat
Sign Up
Cited by 19Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsNeurotransmitter Receptor Influence on Behavior

Carriers of a common variant in the dopamine transporter gene have greater dementia risk, cognitive decline, and faster ventricular expansion

Open access
Roussotte, Florence F., Gutman, Boris A., Hibar, Derrek P., Madsen, Sarah K., Narr, Katherine L., Thompson, Paul M., Alzheimer's Disease Neuroimaging Initiative (ADNI)·2015·Alzheimer's & Dementia
DOI 10.1016/j.jalz.2014.10.011PMC PMC4465053
Open this paper in CoChat — free account

Abstract

Introduction: Genetic variants in DAT1, the gene encoding the dopamine transporter (DAT) protein, have been implicated in many brain disorders. In a recent case‐control study of Alzheimer's disease (AD), a regulatory polymorphism in DAT1 showed a significant association with the clinical stages of dementia. Methods: We tested whether this variant was associated with increased AD risk, and with measures of cognitive decline and longitudinal ventricular expansion, in a large sample of elderly participants with genetic, neurocognitive, and neuroimaging data from the Alzheimer's Disease Neuroimaging Initiative. Results: The minor allele—previously linked with increased DAT expression in vitro—was more common in AD patients than in both individuals with mild cognitive impairment and healthy elderly controls. The same allele was also associated with poorer cognitive performance and faster ventricular expansion, independently of diagnosis. Discussion: These results may be due to reduced dopaminergic transmission in carriers of the DAT1 mutation.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jalz.2014.10.011

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 67

  1. [1]Nieoullon A 2002 Dopamine and the regulation of cognition and attention Prog Neurobiol 67 53 83 12126656
  2. [2]Schuck NW Frensch PA Schjeide BM Schroder J Bertram L 2013 Effects of aging and dopamine genotypes on the emergence of explicit memory during sequence learning Neuropsychologia 24035787
  3. [3]Lin WY Wu BT Lee CC Sheu JJ Liu SH 2012 Association analysis of dopaminergic gene variants (Comt, Drd4 And Dat1) with Alzheimer s disease J Biol Regul Homeost Agents 26 401 410 23034259
  4. [4]Shumay E Fowler JS Volkow ND 2010 Genomic features of the human dopamine transporter gene and its potential epigenetic States: implications for phenotypic diversity PLoS One 5 e11067 20548783 PMC2883569
  5. [5]Vandenbergh DJ Persico AM Hawkins AL Griffin CA Li X 1992 Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR Genomics 14 1104 1106 1478653
  6. [6]Giros B el Mestikawy S Godinot N Zheng K Han H 1992 Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter Molecular pharmacology 42 383 390 1406597
  7. [7]Ciliax BJ Heilman C Demchyshyn LL Pristupa ZB Ince E 1995 The dopamine transporter: immunochemical characterization and localization in brain The Journal of neuroscience: the official journal of the Society for Neuroscience 15 1714 1723 7534339 PMC6578165
  8. [8]Sullivan D Pinsonneault JK Papp AC Zhu H Lemeshow S 2013 Dopamine transporter DAT and receptor DRD2 variants affect risk of lethal cocaine abuse: a gene-gene-environment interaction Transl Psychiatry 3 e222 23340505 PMC3566726
  9. [9]Haddley K Vasiliou AS Ali FR Paredes UM Bubb VJ 2008 Molecular genetics of monoamine transporters: relevance to brain disorders Neurochem Res 33 652 667 17960477
  10. [10]Greenwood TA Alexander M Keck PE McElroy S Sadovnick AD 2002 Segmental linkage disequilibrium within the dopamine transporter gene Mol Psychiatry 7 165 173 11840309
  11. [11]Ono K Takasaki J Takahashi R Ikeda T Yamada M 2013 Effects of antiparkinsonian agents on beta-amyloid and alpha-synuclein oligomer formation in vitro J Neurosci Res 91 1371 1381 23913715
  12. [12]Hua X Hibar DP Ching CR Boyle CP Rajagopalan P 2013 Unbiased tensor-based morphometry: improved robustness and sample size estimates for Alzheimer’s disease clinical trials Neuroimage 66 648 661 23153970 PMC3785376
  13. [13]Stein JL Hua X Morra JH Lee S Hibar DP 2010 Genome-wide analysis reveals novel genes influencing temporal lobe structure with relevance to neurodegeneration in Alzheimer’s disease Neuroimage 51 542 554 20197096 PMC2856746
  14. [14]Folstein MF Folstein SE McHugh PR 1975 “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician J Psychiatr Res 12 189 198 1202204
  15. [15]Leow AD Klunder AD Jack CR Jr Toga AW Dale AM 2006 Longitudinal stability of MRI for mapping brain change using tensor-based morphometry Neuroimage 31 627 640 16480900 PMC1941663
  16. [16]Jack CR Jr Bernstein MA Fox NC Thompson P Alexander G 2008 The Alzheimer’s Disease Neuroimaging Initiative (ADNI): MRI methods J Magn Reson Imaging 27 685 691 18302232 PMC2544629
  17. [17]Chou YY Lepore N de Zubicaray GI Carmichael OT Becker JT 2008 Automated ventricular mapping with multi-atlas fluid image alignment reveals genetic effects in Alzheimer’s disease Neuroimage 40 615 630 18222096 PMC2720413
  18. [18]Chou YY Lepore N Avedissian C Madsen SK Parikshak N 2009 Mapping correlations between ventricular expansion and CSF amyloid and tau biomarkers in 240 subjects with Alzheimer’s disease, mild cognitive impairment and elderly controls Neuroimage 46 394 410 19236926 PMC2696357
  19. [19]Gutman BA Hua X Rajagopalan P Chou YY Wang Y 2013 Maximizing power to track Alzheimer’s disease and MCI progression by LDA-based weighting of longitudinal ventricular surface features Neuroimage 70 386 401 23296188 PMC3942253
  20. [20]Leow AD Yanovsky I Chiang MC Lee AD Klunder AD 2007 Statistical properties of Jacobian maps and the realization of unbiased large-deformation nonlinear image registration IEEE Trans Med Imaging 26 822 832 17679333
  21. [21]Gutman BA Wang Y Thompson PM Rajagopalan P Toga AW 2012 Shape matching with medial curves and 1-D group-wise registration Biomedical Imaging (ISBI), 9th IEEE International Symposium
  22. [22]Yushkevich PA Wang H Pluta J Das SR Craige C 2010 Nearly automatic segmentation of hippocampal subfields in in vivo focal T2-weighted MRI Neuroimage 53 1208 1224 20600984 PMC2939190
  23. [23]Wu C 1980 The 5′ ends of Drosophila heat shock genes in chromatin are hypersensitive to DNase I Nature 286 854 860 6774262
  24. [24]Thurman RE Rynes E Humbert R Vierstra J Maurano MT 2012 The accessible chromatin landscape of the human genome Nature 489 75 82 22955617 PMC3721348
  25. [25]Sheffield NC Thurman RE Song L Safi A Stamatoyannopoulos JA 2013 Patterns of regulatory activity across diverse human cell types predict tissue identity, transcription factor binding, and long-range interactions Genome Res 23 777 788 23482648 PMC3638134
  26. [26]Skelly AC 2011 Probability, proof, and clinical significance Evid Based Spine Care J 2 9 11 23230400 PMC3506143
  27. [27]Patel BB Holland NW 2012 Mild cognitive impairment: hope for stability, plan for progression Cleveland Clinic journal of medicine 79 857 864 23208990
  28. [28]Chen H Foo SH Ury W 2002 Recognizing dementia The Western journal of medicine 176 267 270 12208836 PMC1071748
  29. [29]Ferri CP Prince M Brayne C Brodaty H Fratiglioni L 2005 Global prevalence of dementia: a Delphi consensus study Lancet 366 2112 2117 16360788 PMC2850264
  30. [30]Tang MX Cross P Andrews H Jacobs DM Small S 2001 Incidence of AD in African-Americans, Caribbean Hispanics, and Caucasians in northern Manhattan Neurology 56 49 56 11148235
  31. [32]Murray CJ Lopez AD 1997 Regional patterns of disability-free life expectancy and disability-adjusted life expectancy: global Burden of Disease Study Lancet 349 1347 1352 9149696
  32. [33]Pinsonneault JK Han DD Burdick KE Kataki M Bertolino A 2011 Dopamine transporter gene variant affecting expression in human brain is associated with bipolar disorder Neuropsychopharmacology 36 1644 1655 21525861 PMC3138671
  33. [34]Guindalini C Howard M Haddley K Laranjeira R Collier D 2006 A dopamine transporter gene functional variant associated with cocaine abuse in a Brazilian sample Proc Natl Acad Sci U S A 103 4552 4557 16537431 PMC1450209
  34. [36]LaVoie MJ Hastings TG 1999 Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine The Journal of neuroscience: the official journal of the Society for Neuroscience 19 1484 1491 9952424 PMC6786023
  35. [37]Conway KA Rochet JC Bieganski RM Lansbury PT Jr 2001 Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct Science 294 1346 1349 11701929
  36. [38]Sulzer D 2001 alpha-synuclein and cytosolic dopamine: stabilizing a bad situation Nature medicine 7 1280 1282 11726961
  37. [39]Kuhn DM Francescutti-Verbeem DM Thomas DM 2006 Dopamine quinones activate microglia and induce a neurotoxic gene expression profile: relationship to methamphetamine-induced nerve ending damage Annals of the New York Academy of Sciences 1074 31 41 17105901
  38. [40]Colloby SJ McParland S O’Brien JT Attems J 2012 Neuropathological correlates of dopaminergic imaging in Alzheimer’s disease and Lewy body dementias Brain: a journal of neurology 135 2798 2808 22961551
  39. [41]Piggott MA Marshall EF Thomas N Lloyd S Court JA 1999 Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer’s and Parkinson’s diseases: rostrocaudal distribution Brain: a journal of neurology 122 Pt 8 1449 1468 10430831
  40. [42]Lopez OL Becker JT Kaufer DI Hamilton RL Sweet RA 2002 Research evaluation and prospective diagnosis of dementia with Lewy bodies Archives of neurology 59 43 46 11790229
  41. [43]Bittner V Ullrich G Thormann M Muller NG Friederichs C 2011 Positive FP-CIT SPECT (DaTSCAN) in Clinical Alzheimer’s Disease – An Unexpected Finding? Dementia and geriatric cognitive disorders extra 1 283 291 22545039 PMC3235939
  42. [44]Whitwell JL Jack CR Jr Parisi JE Knopman DS Boeve BF 2007 Rates of cerebral atrophy differ in different degenerative pathologies Brain: a journal of neurology 130 1148 1158 17347250 PMC2752409
  43. [45]Maruyama W Naoi M 2013 “70th Birthday Professor Riederer” induction of glial cell line-derived and brain-derived neurotrophic factors by rasagiline and (−)deprenyl: a way to a disease-modifying therapy? J Neural Transm 120 83 89 22892822
  44. [46]Shah M Rajagopalan S Xu L Voshavar C Shurubor Y 2014 The high-affinity D2/D3 agonist D512 protects PC12 cells from 6-OHDA-induced apoptotic cell death and rescues dopaminergic neurons in the MPTP mouse model of Parkinson’s disease Journal of neurochemistry PMC4177263 24848702
  45. [47]Oster S Radad K Scheller D Hesse M Balanzew W 2014 Rotigotine protects against glutamate toxicity in primary dopaminergic cell culture European journal of pharmacology 724 31 42 24365490
  46. [48]Odaka H Numakawa T Adachi N Ooshima Y Nakajima S 2014 Cabergoline, Dopamine D2 Receptor Agonist, Prevents Neuronal Cell Death under Oxidative Stress via Reducing Excitotoxicity PloS one 9 e99271 24914776 PMC4051758
  47. [49]Gao C Sun X Wolf ME 2006 Activation of D1 dopamine receptors increases surface expression of AMPA receptors and facilitates their synaptic incorporation in cultured hippocampal neurons J Neurochem 98 1664 1677 16800848
  48. [50]Mockett BG Guevremont D Williams JM Abraham WC 2007 Dopamine D1/D5 receptor activation reverses NMDA receptor-dependent long-term depression in rat hippocampus J Neurosci 27 2918 2926 17360914 PMC6672564
  49. [51]Navakkode S Sajikumar S Frey JU 2007 Synergistic requirements for the induction of dopaminergic D1/D5-receptor-mediated LTP in hippocampal slices of rat CA1 in vitro Neuropharmacology 52 1547 1554 17433377
  50. [52]Jurgensen S Antonio LL Mussi GE Brito-Moreira J Bomfim TR 2011 Activation of D1/D5 dopamine receptors protects neurons from synapse dysfunction induced by amyloid-beta oligomers J Biol Chem 286 3270 3276 21115476 PMC3030332
  51. [53]Chapman PF White GL Jones MW Cooper-Blacketer D Marshall VJ 1999 Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice Nat Neurosci 2 271 276 10195221
  52. [54]Mucke L Masliah E Yu GQ Mallory M Rockenstein EM 2000 High-level neuronal expression of abeta 1–42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation J Neurosci 20 4050 4058 10818140 PMC6772621
  53. [55]Walsh DM Klyubin I Fadeeva JV Rowan MJ Selkoe DJ 2002 Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition Biochem Soc Trans 30 552 557 12196135
  54. [56]Yang IA Holloway JW Fong KM 2013 Genetic susceptibility to lung cancer and co-morbidities J Thorac Dis 5 S454 S462 24163739 PMC3804872
  55. [57]Cheng L Han X Shi Y 2009 A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice Am J Physiol Endocrinol Metab 297 E1276 1282 19773578 PMC2793047
  56. [58]Nakanishi H Shindou H Hishikawa D Harayama T Ogasawara R 2006 Cloning and characterization of mouse lung-type acyl-CoA:lysophosphatidylcholine acyltransferase 1 (LPCAT1). Expression in alveolar type II cells and possible involvement in surfactant production J Biol Chem 281 20140 20147 16704971
  57. [59]Blusztajn JK Liscovitch M Mauron C Richardson UI Wurtman RJ 1987 Phosphatidylcholine as a precursor of choline for acetylcholine synthesis J Neural Transm Suppl 24 247 259 3316498
  58. [60]Nakamura S 1996 Phosphatidylcholine hydrolysis and protein kinase C activation for intracellular signaling network J Lipid Mediat Cell Signal 14 197 202 8906562
  59. [61]Zeisel SH 2011 The supply of choline is important for fetal progenitor cells Semin Cell Dev Biol 22 624 628 21693194 PMC3188336
  60. [62]Gaudin M Panchal M Auzeil N Duyckaerts C Brunelle A 2012 Choline-containing phospholipids in microdissected human Alzheimer’s disease brain senile plaque versus neuropil Bioanalysis 4 2153 5159 23013397
  61. [63]Shea TB Ekinci FJ Ortiz D Dawn-Linsley M Wilson TO 2002 Efficacy of vitamin E, phosphatidyl choline, and pyruvate on buffering neuronal degeneration and oxidative stress in cultured cortical neurons and in central nervous tissue of apolipoprotein E-deficient mice Free Radic Biol Med 33 276 282 12106823
  62. [64]Tiraboschi P Hansen LA Alford M Merdes A Masliah E 2002 Early and widespread cholinergic losses differentiate dementia with Lewy bodies from Alzheimer disease Archives of general psychiatry 59 946 951 12365882
  63. [65]Chen SG Kulju D Halt S Murakami K 1992 Phosphatidylcholine-dependent protein kinase C activation. Effects of cis-fatty acid and diacylglycerol on synergism, autophosphorylation and Ca(2+)-dependency Biochem J 284 Pt 1 221 226 1599399 PMC1132719
  64. [66]Neve KA Seamans JK Trantham-Davidson H 2004 Dopamine receptor signaling J Recept Signal Transduct Res 24 165 205 15521361
  65. [67]Martorana A Mori F Esposito Z Kusayanagi H Monteleone F 2009 Dopamine modulates cholinergic cortical excitability in Alzheimer’s disease patients Neuropsychopharmacology 34 2323 2328 19516251
  66. [68]Martorana A Di Lorenzo F Esposito Z Lo Giudice T Bernardi G 2013 Dopamine D(2)-agonist rotigotine effects on cortical excitability and central cholinergic transmission in Alzheimer’s disease patients Neuropharmacology 64 108 113 22863599
  67. [69]Cummings JL 2008 Integrating symptomatic- and disease-modifying treatments CNS Spectr 13 28 30 18955958

Cited by

Sorted by citations

Authors
Roussotte, F. F., Gutman, B. A., Hibar, D. P., Madsen, S. K., Narr, K. L., Thompson, P. M., & (ADNI), A. D. N. I.
Affiliations
  • University of Southern California (US)
  • University of California, Los Angeles (US)
Corresponding author
Thompson, Paul M.
ORCID
Venue
Alzheimer's & Dementia
Publisher
Wiley
Published
2014-12-10
Volume
11
Issue
10
Pages
1153-1162
ISSN
  • 1552-5260 (ISSN-L)
  • 1552-5279
DOI
10.1016/j.jalz.2014.10.011
PMC
PMC4465053
OpenAlex
W2033188976
Cited by
19
References
3
Citations by year
2026: 3 · 2024: 1 · 2023: 2 · 2022: 3 · 2021: 4 · 2020: 1 · 2018: 1 · 2017: 3 · 2015: 1
FWCI
1.02
Type
journal article
Language
en
Open access
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations
  • Alzheimer s & Dementia (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • A.P. Giannini Foundation
  • National Institutes of Health (R01 MH097268, R01 AG040060, U01 AG024904)
  • Alzheimer's Disease Neuroimaging Initiative
  • National Institute on Aging
  • National Institute of Biomedical Imaging and Bioengineering
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
dopamine transporter gene, DAT1
MeSH terms
Aged, Aged, 80 and over, Alleles, Alzheimer Disease, Cerebral Ventricles, Cognition, Female, Genotype, Heterozygote, Humans, Magnetic Resonance Imaging, Male, Polymorphism, Genetic, Risk, Case-Control Studies, Dopamine Plasma Membrane Transport Proteins, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review